Last reviewed · How we verify
Catechin (CIANIDANOL)
At a glance
| Generic name | CIANIDANOL |
|---|---|
| Target | Carbonic anhydrase 7 |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 1977 |
Approved indications
- Condyloma acuminatum
Common side effects
Key clinical trials
- Epigallocatechin Gallate (EGCG) as a Flushing Agent During Full Pulpotomy in Mature Permanent Molars With Irreversible Pulpitis (NA)
- To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring (PHASE2)
- A One Visit Follow Up of Adults With Fabry Disease Who Started Long-term Enzyme Replacement Therapy As Children (NA)
- Biomarker-estimated Flavanol Intake in Davis (FID)
- Cocoa to Maximize Exercise Training in Older Adults - The COMET Trial (PHASE1,PHASE2)
- Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19.
- Nutrition to Support Postoperative Recovery (NA)
- PSYLIVER-PILOTE: Involvement of the Autonomic Nervous System in Hepatocellular Carcinoma (HCC) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Catechin CI brief — competitive landscape report
- Catechin updates RSS · CI watch RSS